Medium term milestones, page-26

If Daybue goes blockbuster 2024 assuming in US 300-400 patient uptake a quarter is maintained, followed by ROW coming online with assumed similar uptake.

Yes then with milestones and royalties Neu could go it alone.

We have to remember that the likelihood of getting through phase 2 trial is 26% average, getting x 4 indications through is far less, so Neu may initially in reality only need to fund x 2 2591 phase 3 trials.

Will have to wait and see, I suspect if all x 4 come up successful in ph 2's then we will be taken out at a premium given the odds of success for 1, to get x 4 would be incredible and make a clear statement about 2591!